Bundled hyperpolypharmacy intervention for Polypharmacy

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Polypharmacy
Bundled hyperpolypharmacy - Other
Eligibility
65+
All Sexes
What conditions do you have?
Select

Study Summary

Older patients using many prescription drugs (hyperpolypharmacy) may be at increased risk of adverse drug effects. This randomized controlled trial tested the effectiveness and safety of a quality intervention intended to reduce hyperpolypharmacy. The study was set at Kaiser Permanente Northern California, an integrated health system with multiple pre-existing deprescribing workflows. Eligible patients were aged ≥76 years using ≥10 prescription medications. The intervention included physician-pharmacist collaborative drug therapy management, standard-of-care practice recommendations, shared decision-making, and deprescribing protocols administered by telephone over multiple cycles for a maximum of 180 days after allocation. A priori primary effectiveness endpoints included change in the number of medications and in the prevalence of geriatric syndrome from 181-365 days after allocation. Second endpoints included utilization and adverse drug withdrawal effects. Information was obtained from the electronic health record.

Treatment Effectiveness

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: Difference between (days 181-365 after randomization) and (180 days before randomization)

Day 181
Adverse drug withdrawal effects
Pharmaceutical Preparations
Syndrome
Utilization

Trial Safety

Trial Design

2 Treatment Groups

Control
1 of 2
Bundled hyperpolypharmacy intervention
1 of 2

Active Control

Experimental Treatment

2471 Total Participants · 2 Treatment Groups

Primary Treatment: Bundled hyperpolypharmacy intervention · No Placebo Group · N/A

Bundled hyperpolypharmacy intervention
Other
Experimental Group · 1 Intervention: Bundled hyperpolypharmacy · Intervention Types: Other
ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: difference between (days 181-365 after randomization) and (180 days before randomization)

Who is running the clinical trial?

Kaiser PermanenteLead Sponsor
507 Previous Clinical Trials
22,272,341 Total Patients Enrolled
3 Trials studying Polypharmacy
1,178 Patients Enrolled for Polypharmacy
Lisa Herrinton, PhDPrincipal InvestigatorKaiser Permanente

Eligibility Criteria

Age 65+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The patient is taking 10 or more drugs.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: November 16th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.